NO20083877L - Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelser - Google Patents
Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelserInfo
- Publication number
- NO20083877L NO20083877L NO20083877A NO20083877A NO20083877L NO 20083877 L NO20083877 L NO 20083877L NO 20083877 A NO20083877 A NO 20083877A NO 20083877 A NO20083877 A NO 20083877A NO 20083877 L NO20083877 L NO 20083877L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- compositions
- treatment
- inflammatory disorders
- immune inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Oppfinnelsen angår metoder og sett for behandling av en immunoinflammatorisk lidelse, ved administrering til en pasient diagnostisert med eller med risiko for å utvikle en slik immunoinflammatorisk lidelse, av en adenosin-aktivitet-oppregulator i kombinasjon med ett eller flere ytterligere midler.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78002806P | 2006-03-07 | 2006-03-07 | |
PCT/US2007/005694 WO2007103373A2 (en) | 2006-03-07 | 2007-03-06 | Compositions and methods for the treatment of immunoinflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083877L true NO20083877L (no) | 2008-12-02 |
Family
ID=38475501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083877A NO20083877L (no) | 2006-03-07 | 2008-09-10 | Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelser |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070213296A1 (no) |
EP (1) | EP1993540A4 (no) |
JP (1) | JP2009529053A (no) |
KR (1) | KR20080112270A (no) |
AU (1) | AU2007223988A1 (no) |
CA (1) | CA2644889A1 (no) |
IL (1) | IL193936A0 (no) |
NO (1) | NO20083877L (no) |
WO (1) | WO2007103373A2 (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005508346A (ja) * | 2001-10-05 | 2005-03-31 | コンビナトアールエックス インコーポレーティッド | 免疫炎症疾患の治療のための組合せ |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
CA2652773A1 (en) * | 2006-05-22 | 2007-12-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels |
US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
US7541384B2 (en) | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
US8436051B2 (en) * | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
KR20100121601A (ko) * | 2007-12-17 | 2010-11-18 | 콤비네이토릭스, 인코포레이티드 | 면역염증성 질환의 치료를 위한 치료요법 |
CN102186458A (zh) | 2008-10-14 | 2011-09-14 | 艾克蒂维罗有限责任公司 | 治疗慢性阻塞性肺病及其它肺疾病的方法 |
US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
AU2013203957B9 (en) * | 2012-04-16 | 2015-10-15 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Glucocorticoids |
WO2015200094A1 (en) * | 2014-06-20 | 2015-12-30 | Baylor Research Institute | Methods and compositions for systemic lupus erythematosus (sle) therapy |
CA2950475C (en) | 2014-06-26 | 2022-08-30 | F. Hoffmann-La Roche Ag | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
KR102255308B1 (ko) * | 2014-11-18 | 2021-05-24 | 삼성전자주식회사 | 아세틸살리실산을 포함하는 개체의 스테로이드 부작용을 예방 또는 치료하기 위한 조성물 및 그의 용도 |
HUE050083T2 (hu) | 2015-11-06 | 2020-11-30 | Hoffmann La Roche | Indolin-2-on származékok |
CN108349942B (zh) | 2015-11-06 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物 |
US20190282580A1 (en) * | 2016-11-10 | 2019-09-19 | La Jolla Institute For Allergy And Immunology | Pro-inflammatory role for adenosine uptake and metabolism |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996036611A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
AU7127600A (en) * | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
UA82323C2 (uk) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
-
2007
- 2007-03-06 CA CA002644889A patent/CA2644889A1/en not_active Abandoned
- 2007-03-06 AU AU2007223988A patent/AU2007223988A1/en not_active Abandoned
- 2007-03-06 JP JP2008558356A patent/JP2009529053A/ja active Pending
- 2007-03-06 KR KR1020087024413A patent/KR20080112270A/ko not_active Application Discontinuation
- 2007-03-06 WO PCT/US2007/005694 patent/WO2007103373A2/en active Application Filing
- 2007-03-06 EP EP07752398A patent/EP1993540A4/en not_active Withdrawn
- 2007-03-06 US US11/714,967 patent/US20070213296A1/en not_active Abandoned
-
2008
- 2008-09-07 IL IL193936A patent/IL193936A0/en unknown
- 2008-09-10 NO NO20083877A patent/NO20083877L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1993540A2 (en) | 2008-11-26 |
KR20080112270A (ko) | 2008-12-24 |
AU2007223988A1 (en) | 2007-09-13 |
JP2009529053A (ja) | 2009-08-13 |
CA2644889A1 (en) | 2007-09-13 |
WO2007103373A3 (en) | 2008-09-18 |
WO2007103373A2 (en) | 2007-09-13 |
IL193936A0 (en) | 2009-08-03 |
EP1993540A4 (en) | 2010-06-09 |
US20070213296A1 (en) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083877L (no) | Sammensetninger og fremgangsmater for behandling av immunoinflammatoriske forstyrrelser | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
NO20083303L (no) | Fremgangsmater, sammensetinger og sett for behandling av muskel-skjelettsykdommer og symptomer assosiert dermed | |
NO20082473L (no) | Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander | |
NO20075821L (no) | Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner | |
CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
NO20062003L (no) | Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser | |
NO20083202L (no) | ANG2- og VEFG-inhibitorkombinasjoner | |
NO20061239L (no) | Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser | |
EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
ATE482209T1 (de) | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität | |
MX2012010418A (es) | Inhibidores syk de imidazopiridinas. | |
EA201400197A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
NO20084374L (no) | Imidazoltiazolforbindelser for behandling av sykdom | |
DK1830881T3 (da) | Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf | |
TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
MA38567A1 (fr) | Variantes de pertuzumab et leur évaluation | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
EA201001749A1 (ru) | Способ лечения недифференцированного артрита | |
BR112016028446A2 (pt) | inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5 | |
TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |